'If you had to pick one of this week's big losers, which would it be? My choice would be Keryx. Despite worries about patents and NCE status, the company has a lot of good things going for it. Investors will probably be in for something of a roller-coaster ride with this stock, but there should still be plenty of room to move upward over the long run."
The stock is substantially undervalued. With "big pharma" drug companies expected to spend more than $65,000,000,000 in M & A activity in 2013 Keryz is a prime takeover target.
The company's C.E.O. will be presenting tomorrow at the 15th Annual BIO CEO & Investor
Conference. Mr. Bentsur's presentation is scheduled at 2:30 PM ET. A live audio webcast of his presentation will be accessible from the Investor Information page of the company's website.
Should end the week above $8.00. It's oversold here.